Skip to main content

Advertisement

Table 3 Multivariate analyses of 34 antibodies for interaction with chemotherapy arm

From: Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC - PACS 01 randomized trial

Marker Category N Arms A/B Adjusted Hazard ratio (95% CI) P-value forinteraction
AF6 Neg. 99/94 0.94 (0.50 to 1.79) 0.663
  Pos. 321/335 0.86 (0.61 to 1.23)  
Angiogenin Neg. 34/37 1.68 (0.47 to 5.96) 0.1
  Pos. 439/440 0.66 (0.49 to 0.89)  
Aurora A Neg. 293/292 0.91 (0.62 to 1.33) 0.228
  Pos. 135/141 0.61 (0.38 to 1.00)  
BCL2 Neg. 184/193 0.78 (0.52 to 1.17) 0.905
  Pos. 285/295 0.80 (0.54 to 1.19)  
α-Catenin Neg. 177/182 0.85 (0.53 to 1.37) 0.875
  Pos. 250/251 0.79 (0.53 to 1.16)  
β-Catenin Neg. 123/142 1.19 (0.69 to 2.05) 0.14
  Pos. 324/312 0.67 (0.47 to 0.96)  
CAV1 Neg. 82/97 1.11 (0.50 to 2.44) 0.229
  Pos. 389/389 0.69 (0.51 to 0.94)  
CD10 Neg. 197/212 0.87 (0.55 to 1.38) 0.741
  Pos. 259/249 0.77 (0.54 to 1.12)  
CD44 Neg. 210/220 0.63 (0.41 to 0.96) 0.158
  Pos. 128/152 1.03 (0.61 to 1.73)  
CK5/6 Neg. 122/126 0.84 (0.48 to 1.48) 0.96
  Pos. 332/335 0.79 (0.56 to 1.10)  
CK8/18 Neg. 13/9 4.73 (0.96 to 23.3) 0.446
  Pos. 468/480 0.69 (0.52 to 0.91)  
CK14 Neg. 386/388 0.77 (0.56 to 1.05) 0.142
  Pos. 84/74 0.41 (0.18 to 0.90)  
Cyclin D1 Neg. 161/155 0.78 (0.48 to 1.26) 0.974
  Pos. 317/331 0.78 (0.55 to 1.10)  
E-Cadherin Neg. 62/66 1.77 (0.69 to 4.59) 0.154
  Pos. 432/441 0.71 (0.53 to 0.95)  
EGFR Neg. 401/413 0.85 (0.63 to 1.16) 0.235
  Pos. 95/90 0.58 (0.30 to 1.13)  
ER Neg. 137/146 0.79 (0.52 to 1.22) 0.976
  Pos. 394/391 0.79 (0.56 to 1.10)  
FGFR1 Neg. 56/58 0.32 (0.10 to 1.02) 0.178
  Pos. 306/320 0.84 (0.59 to 1.19)  
FHIT Neg. 127/110 0.00 (0.52 to 1.90) 0.473
  Pos. 321/351 0.73 (0.52 to 1.01)  
GATA3 Neg. 88/78 0.74 (0.40 to 1.37) 0.908
  Pos. 407/409 0.74 (0.54 to 1.02)  
HER2 Neg. 451/466 0.85 (0.63 to 1.15) 0.367
  Pos. 93/82 0.65 (0.36 to 1.17)  
Ki67 Neg. 327/334 1.10 (0.75 to 1.61) 0.012
  Pos. 147/133 0.51 (0.33 to 0.79)  
MET Neg. 301/301 0.91 (0.63 to 1.30) 0.154
  Pos. 150/165 0.59 (0.38 to 0.94)  
Moesin Neg. 412/412 0.77 (0.57 to 1.05) 0.92
  Pos. 56/62 0.80 (0.39 to 1.65)  
MUC1 Neg. 53/42 0.73 (0.32 to 1.70) 0.651
  Pos. 461/477 0.73 (0.55 to 0.98)  
P21 Neg. 187/191 0.74 (0.48 to 1.14) 0.879
  Pos. 272/273 0.76 (0.51 to 1.13)  
P27 Neg. 78/97 0.76 (0.41 to 1.42) 0.826
  Pos. 378/390 0.73 (0.53 to 1.00)  
P53 Neg. 364/382 0.76 (0.54 to 1.08) 0.74
  Pos. 123/123 0.71 (0.45 to 1.13)  
P-Cadherin Neg. 282/288 0.78 (0.52 to 1.17) 0.622
  Pos. 179/192 0.68 (0.46 to 1.02)  
PR Neg. 255/233 0.86 (0.61 to 1.22) 0.601
  Pos. 276/305 0.76 (0.50 to 1.15)  
PTEN Neg. 152/162 0.99 (0.60 to 1.64) 0.221
  Pos. 315/295 0.68 (0.47 to 0.97)  
TACC2 Neg. 70/78 0.54 (0.25 to 1.20) 0.397
  Pos. 366/357 0.87 (0.63 to 1.19)  
TACC3 Neg. 13/22 0.29 (0.04 to 2.14) 0.363
  Pos. 284/280 0.97 (0.67 to 1.41)  
TAU Neg. 340/345 0.83 (0.59 to 1.16) 0.611
  Pos. 65/76 0.96 (0.38 to 2.42)  
TOPO2A Neg. 104/95 0.82 (0.39 to 1.74) 0.917
  Pos. 359/355 0.77 (0.56 to 1.06)